SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Higuchi Ichiyō — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientHiguchi Ichiyō
Date of birth1872-05-02
IdentifiersMRN HR-NI029-SYN-TD; SSN (made up) 000-29-5108
Document date1896-06-12
AuthorAiko Lindgren-Tanaka, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

End of the eight-week intensive phase. [S]

History of Present Illness

Ms. Higuchi returns at the end of the intensive phase, having taken all 56 doses by video, the last pyrazinamide dose yesterday. The isolate was susceptible to isoniazid, rifampin, pyrazinamide and ethambutol, and ethambutol was stopped by phone three weeks ago when the result arrived. The two-week sputum showed no acid-fast bacilli, and its culture has had no growth. The cough has gone and the night sweats stopped a month ago. She has no nausea, yellowing, dark urine, abdominal pain, numbness, or change in vision. She is eating well and has gained 2.5 kg. She is writing two hours each morning and has sent a story to an editor. [S]

ElementDetail
Treatment56 of 56 intensive-phase doses observed; ethambutol stopped three weeks ago
SusceptibilitySusceptible to all four first-line drugs
SymptomsNo cough or night sweats
Weight41.0 kg, up 2.5 kg

Review of Systems

SystemResultFinding
RespiratoryNegativeNo cough or sputum; not breathless
ConstitutionalNegativeNo fever or night sweats; energy better
GastrointestinalNegativeNo nausea, abdominal pain or jaundice
EyesNegativeNo change in vision or colors
PsychiatricNegativeMood better; PHQ-9 5

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 100 mg tablets, two tablets (200 mg) daily200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route1896-04-17 to 1896-10-15completedS
Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route1896-04-17 to 1896-10-15completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phaseOral route1896-04-17 to 1896-06-11completedS
Ethambutol 100 mg tablets, six tablets (600 mg) daily600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results returnOral route1896-04-17 to 1896-05-22stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route1896-04-17 to 1896-10-15completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1896-06-12Body height148cmS
1896-06-12Body weight41kgS
1896-06-12Body mass index (BMI) [Ratio]18.7kg/m2S
1896-06-12Systolic blood pressure102mm[Hg]S
1896-06-12Diastolic blood pressure64mm[Hg]S
1896-06-12Heart rate80/minS
1896-06-12Respiratory rate16/minS
1896-06-12Body temperature36.8CelS
1896-06-12Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1896-06-12Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-35 U/LNormalS
1896-06-12Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma25U/L10-35 U/LNormalS
1896-06-12Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
1896-06-12Albumin [Mass/volume] in Serum or Plasma3.8g/dL3.5-5 g/dLNormalS
1896-06-12Hemoglobin [Mass/volume] in Blood12.4g/dL12-15.5 g/dLNormalS
1896-06-12Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
1896-06-12Visual acuity uncorrected Left eye by ETDRS eye chart85{letters}>=80NormalS
1896-06-12Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S

Physical Exam

Vital signs recorded on 1896-06-12; see the Vital Signs section. [S]

SystemFinding
GeneralLooks well; weight 41.0 kg, BMI 18.7; temperature 36.8 °C, pulse 80
EyesNo icterus. Visual acuity 85 letters in each eye; Ishihara plates normal
RespiratoryClear on both sides
AbdomenSoft and non-tender
NeurologicalNormal sensation in the feet

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and cultureresolvedconfirmed R05.3S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D).
Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected)activeconfirmed A15.0S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic.
Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dLactiveconfirmed E44.0S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty.
Low and irregular income from writing, with a household to support; costs of care are a barrieractiveconfirmed Z59.6S — Synthetic social need anchored to her documented poverty and household responsibilities.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptom review: cough, sputum, fever, night sweatsAt least monthly during treatmentCompleted todayNo cough, fever or night sweats
Self-managementWeight and nutritionEvery visit; dose review if weight changes by more than about 5 kgCompleted today41.0 kg, up 2.5 kg; albumin 3.8 g/dL; doses unchanged
Medication safetyHepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine)Every visit and every observed doseCompleted todayNo symptoms
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptomsCompleted todayALT 26, AST 25 U/L, bilirubin 0.5 mg/dL, all normal
LaboratoryMonthly liver tests in the intensive phase (month one)Monthly in the intensive phase because of low weight and albuminDeferredMissed: the liver tests due about four weeks into treatment were not drawn, because no visit was booked and the phone call that stopped ethambutol did not include a blood test. No harm judging by today's normal results and the absence of symptoms at every observed dose. Corrective action: blood tests due between visits are now booked as laboratory visits with a reminder to the observing nurse
ImagingVisual acuity and color visionBaseline and monthly while on ethambutolDeferredMissed: the monthly vision check due about four weeks into treatment, while she was still taking ethambutol, was not done for the same reason. No harm: acuity 85 letters in each eye and normal color vision today, three weeks after ethambutol was stopped. Corrective action: any future ethambutol course is booked with monthly vision checks
LaboratoryDrug susceptibility testing of the first isolateOnce, on the first positive cultureCompleted todaySusceptible to isoniazid, rifampin, pyrazinamide and ethambutol; ethambutol stopped three weeks ago
LaboratoryTwo-month sputum smear and cultureAt the end of the intensive phaseCompleted todayTwo-week specimen smear-negative with no growth so far; two-month induced specimen sent today
LaboratoryBlood countAt diagnosis, then as neededCompleted todayHemoglobin 12.4 g/dL, up from 11.4
Medication safetyContinuation-phase lengthAt the end of the intensive phaseCompleted todayFour months planned, because there was no cavity; extension to seven months would be considered if the two-month culture were positive, because she is underweight
Medication safetyDoses observed and missed (video-observed therapy)Every visitCompleted today56 of 56 doses observed
Medication safetyPeripheral neuropathy check, with pyridoxineEvery visitCompleted todayNo neuropathy; pyridoxine continues
Medication safetyRifampin drug-interaction review, including hormonal contraceptionWith every new medicineCompleted todayNo new medicines
ReferralContact investigation (household and close contacts)Led by the public health center, from diagnosisReferredContinuing with the public health center; results not part of her record
SurveyDepression screen (PHQ-9)At diagnosis, at two months, and at the end of treatmentCompleted todayPHQ-9 5, from 8; item 9 scored 0

Goal progress:

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025); WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022); Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Two-month culture result by phone. Preventive visit as booked. End-of-treatment visit after the 182nd dose. Call for cough, fever, weight loss, hepatitis symptoms or numbness. Next scheduled visit 1896-08-24: periodic adult preventive visit. [S]